• Active, not recruiting

NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma

Updated: Oct 3

MagnetisMM-3

NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma

MagnetisMM-3

Relapsed & Refractory Multiple Myeloma

The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb


Sponsor

Pfizer


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT04649359

Official Title: MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY

First Posted : December 2, 2020


Click here for details on Clinicaltrials.gov


You don’t have to take on multiple myeloma alone | Pfizer Clinical Trials

 

Elranatamab


Elranatamab (Code C146860)

Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135

B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135

BCMA x CD3 Bispecific Antibody PF-06863135

BCMA-CD3 Bispecific Ab PF-06863135

Elranatamab

ELRANATAMAB

PF 06863135

PF-06863135

PF06863135

RN 613

RN-613

RN613

 

Meeting: 2022 ASCO Annual Meeting - Session Type: Oral Abstract Session - Session Title: Hematologic Malignancies—Plasma Cell Dyscrasia - Track: Hematologic Malignancies - Sub Track: Hematologic Malignancies - Clinical Trial Registration Number: NCT04649359

Abstract#: 8006 - Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).

Click here to read abstract details

 

ABSTRACTS & PRESENTATIONS

2022 ASCO ANNUAL MEETING - June 3-7, 2022 - McCormick Place, Chicago, IL - Hybrid Meeting

2022 ASCO Annual Meeting - Oral Abstract Session

Click here for details

 

- Florida: Miami Cancer Institute

- Georgia: Emory University Atlanta

- Iowa: University of Iowa Iowa city

- Massachusetts: Massachusetts General Hospital Boston

- New Jersey: Hackensack University Medical Center

- New York: Roswell Park Cancer Institute Buffalo

- New York: Memorial Sloan-Kettering Cancer Center New York

- New York: New York Presbyterian / Weill Cornell Medical College New York

- Pennsylvania: Fox Chase Cancer Center Philadelphia

- Texas: Baylor University Medical Center Dallas

 

Locations

United States, California

United States, Florida

United States, Georgia

United States, Illinois

United States, Indiana

United States, Iowa

United States, Kentucky

United States, Louisiana

United States, Massachusetts

United States, New Jersey

United States, New York

United States, Pennsylvania

United States, South Carolina

United States, Texas


Canada, Alberta

Canada, Quebec


Europe

United Kingdom

France

Germany

Spain

Belgium

Poland

Asia

Japan

Australia, Victoria

 

RELATED POSTS


MagnetisMM-1

NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma - MagnetisMM-1

Click here for details


MAGNETISMM-2

NCT04798586: Phase 1: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma - MAGNETISMM-2

Click here for details


MagnetisMM-4

NCT05090566: Phase 2: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM - MagnetisMM-4

Click here for details


MagnetisMM-5

NCT05020236: Phase 3: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex - MagnetisMM-5

Click here for details


MagnetisMM-7

NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7

Click here for details


MagnetisMM-8

NCT05228470: Phase 2: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM - MagnetisMM-8

Click here for details


MagnetisMM-9

NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9

Click here for details


NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

Click here for details







Posts Archive